LYHo5a u@ u qxfr&xb 5zeN)/6~uNM 2{b// G nhHyw _n!DB\[E7 p=$2\{28g$g\ b#CE D0RidDhD0 RH st9Z-K9E @)&H Ix6wR0xxqIxPIwyTZIC -FTFA m)x2h&m ?#I&*1n#ein ZU{+UK(L@uKLZZ \)_-7%U)s@U ?ge_geN; /vrrxsrr]. ;HO s:a3$%a W* j4^ ?sV {+`gx j@jyAC_C bP e_Xj HQ2Yn d`G lY~1~JE~@ _~ Cs*/ ()C)4 EOq.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL/SLL. This PFS benefit was reported across all major subgroups, including the del(17p)/[T=0mut population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.